The Patent Finder

Terms ending in 2033

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 9,714,294Monoclonal Antibodies Against HER2 Epitope
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,230,604Antibodies Against Human CD38
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,866,514Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
In force
 · Medium confidence
Genmab A/SIn forceMedium confidence
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited